1.

High levels of uPA and PAI-1 predict a good response to anthracyclines.

The present paper confirms our previous observation that worse prognosis correlated with high uPA and PAI-1 levels can be reversed with improved treatment efficacy achieved by anthracycline-based chemotherapy, and not by CMF. Patients with high uPA and/or PAI-1 levels in the primary tumor may benefit more from the adjuvant anthracycline-containing regimens than from CMF. The clinical application of the present work is to offer additional information that might facilitate the selection of the most appropriate candidates for anthracycline-based chemotherapy.

COBISS.SI-ID: 843131

2.

KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment.

In the study, we validated the method for the detection of KRAS mutations. Among the tested patients, 54.5% had a wt-KRAS genotype and 45.5% had a mutated KRAS genotype. The p.Gly12Asp was the most common detected mutation (38.5%). Among the cetuximab therapy responders, 85.7% had a wt-KRAS genotype.

COBISS.SI-ID: 889211

3.

Screening of TERC gene amplification as an additional genetic diagnostic test in detection of cervical preneoplastic lesions.

Authors are describing the role of TERC gene amplification in detection of cervical intraepithelial neoplasia.

COBISS.SI-ID: 3500607

4.

Sensitivity and reproducibility of PCR assays for detection of the t(14;18) translocation in biopsy material from patients with follicular lymphoma.

Fifty and seven formalin-fixed, paraffin-embedded tumor lymph node specimens from 50 patients with follicular lymphoma were included in the study. Overall detection rate of the t(14;18) in our study (52.6%) was in accordance with the literature. The most sensitive method was LightCycler®-based PCR with detection rate of 47.4%, followed by MBR1,2 assay (43.9%). We observed a good agreement between qualitative MBR1,2 and quantitative LightCycler®-based assay with a slightly higher detection rate of the quantitative method.

COBISS.SI-ID: 689275

5.

Treatment of NonHodgkin's lymphomas with rituximab in Slovene patients.

The addition of rituximab to chemotherapy improves the overall response rate, prolongs the response duration and the overall survival both in patients with follicular and other indolent CD20 positive lymphomas and diffuse large B cell lymphomas. In the period from 2004 to 2006, we have treated 340 patients with rituximab. The highest response rate was achieved in patients with aggressive follicular lymphomas (91.7%), the longest disease free survival was observed in patients with diffuse large B cell lymphomas and the longest overall survival in patients with indolent follicular lymphomas.

COBISS.SI-ID: 720507